

Addict Behav. Author manuscript; available in PMC 2011 May 1.

Published in final edited form as:

Addict Behav. 2010 May; 35(5): 517–521. doi:10.1016/j.addbeh.2009.12.019.

Sexual Orientation and Drug Use in a Longitudinal Cohort Study of U.S. Adolescents

Heather L. Corliss, MPH, $PhD^{1,2,*}$, Margaret Rosario, PhD^3 , David Wypij, $PhD^{2,4,5}$, Sarah A. Wylie, BA^1 , A. Lindsay Frazier, MD, $ScM^{6,7}$, and S. Bryn Austin, $ScD^{1,2,6,8}$

¹Division of Adolescent and Young Adult Medicine, Children's Hospital, Boston

²Department of Pediatrics, Harvard Medical School, Boston

³City University of New York, City College and Graduate Center, New York

⁴Department of Biostatistics, Harvard School of Public Health, Boston

⁵Department of Cardiology, Children's Hospital, Boston

⁶Channing Laboratory, Department of Medicine, Brigham and Women's Hospital, and Harvard Medical School, Boston

⁷Dana Farber Cancer Institute, Boston

⁸Department of Society, Human Development and Health, Harvard School of Public Health, Boston

Abstract

Adolescents with a minority sexual orientation (e.g., lesbian, gay, bisexual) are more likely to use substances than their heterosexual peers. This study aimed to increase understanding of the development of drug use in this vulnerable population by: 1) comparing longitudinal patterns of past-year illicit drug use (e.g., marijuana, cocaine, ecstasy) and misuse of prescription drugs among minority sexual orientation youth relative to heterosexual youth and, 2) examining how sexual orientation subgroup, gender, and age relate to variation in risk of drug use. Data come from the Growing Up Today Study, a community-based cohort of adolescents who were assessed three times between 1999–2005 with self-administered questionnaires when they ranged in age from 12 to 23 years (N=12,644; 74.9% of the original cohort). Multivariable repeated measures generalized estimating equations using modified Poisson regression was used to estimate relative risks. Participants indicating their sexual orientation was mostly heterosexual, bisexual, or lesbian/gay were more likely than completely heterosexual youth to report past-year illicit drug use and misuse of prescription drugs. Gender was an important modifier; bisexual females were most likely to report

Drs. Corliss and Austin designed the study. Dr. Corliss and Ms. Wylie conducted data analysis. Dr. Wypij provided statistical consultation. All authors participated in data interpretation. Dr. Corliss wrote the first draft of the manuscript. All authors contributed to critical revisions of the manuscript for important intellectual content and have approved the final manuscript. Drs. Corliss, Austin, and Frazier obtained funding.

Conflict of Interest

All authors declare that they have no conflicts of interest.

^{© 2009} Elsevier Ltd. All rights reserved.

^{*}Corresponding author. Division of Adolescent and Young Adult Medicine, Children's Hospital Boston, 300 Longwood Avenue, Boston, MA 02115. Tel.: 617-355-8695; fax: 617-730-0195; heather.corliss@tch.harvard.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Contributors

drug use. Age was also an important modifier of risk; differences in drug use between minority sexual orientation and heterosexual youth were larger during adolescence (12–17 years) than during emerging adulthood (18–23 years). Research must focus on identifying reasons why minority sexual orientation youth are at disproportionate risk for drug use. Such information is essential for developing interventions that are critically needed to reduce drug use in this population. Efforts need to begin early because large sexual orientation disparities in drug use are evident by adolescence.

Keywords

illicit drug use; prescription drug misuse; adolescence; young adult; sexual orientation; gay; lesbian; bisexual; heterosexual; epidemiology; longitudinal study

1. Introduction

Adolescents who identify as lesbian, gay, or bisexual, or who report same-sex attractions and/or relationships are at disproportionate risk for using drugs (Marshal, et al., 2008). Evidence of sexual orientation disparities in adolescent drug use comes primarily from cross-sectional studies of high school (e.g., Faulkner & Cranston, 1998; Garofalo, Wolf, Kessel, Palfrey, & DuRant, 1998) or college (e.g., Eisenberg & Wechsler, 2003; Ford & Jasinski, 2006; McCabe, 2005) samples. These studies have found that minority sexual orientation youth are more likely than heterosexuals to report use of marijuana, cocaine, and other illicit drugs, and prescription drug misuse.

Despite evidence of greater drug use in this population, outstanding questions remain. There is uncertainty whether drug use vulnerability varies by age or developmental period (e.g., adolescence, young adulthood). Younger age of use is associated with worse sequelae (Fergusson, Boden, & Horwood, 2006; Lubman, Yucel, & Hall, 2007). There is also uncertainty about how gender and sub-group status (e.g., lesbian/gay, bisexual) influence risk of adolescent drug use. Sexual orientation disparities in substance use may be larger in females than males (Russell, Driscoll, & Truong, 2002). A community-based study of gay, lesbian, and bisexual youth found that females were more likely to report substance use than males (Rosario, Hunter, & Gwadz, 1997). In contrast, studies with general adolescent samples find that males are more than or equally as likely as females to report drug use (Substance Abuse and Mental Health Services Administration [SAMHSA], 2008). Studies also suggest that among females, bisexuals are at elevated risk for drug use compared to lesbians or heterosexuals (Eisenberg & Wechsler, 2003; Ford & Jasinski, 2006; Russell, et al., 2002). However, the extent to which gender and sexual orientation sub-group differences emerge during adolescence and how differences may vary across developmental periods remain understudied.

A recent meta-analysis and methodological review underscored the large gaps in understanding how sexual orientation is related to longitudinal substance use and identifying the most vulnerable subgroups (Marshal, et al., 2008). Our study objectives were to: 1) estimate sexual orientation differences in longitudinal patterns of past-year drug use among youth across ages 12 to 23 years; 2) examine if gender modified sexual orientation differences in risk of past-year drug use; and 3) explore whether developmental period [adolescence versus emerging adulthood (Arnett, 2000)] modified associations between sexual orientation and drug use.

2. Methods

2.1. Study Participants

Data come from the Growing Up Today Study (GUTS), a longitudinal cohort study of children of Nurses' Health Study II participants (Brigham and Women's Hospital and Harvard Medical

School, 2009) begun in 1996 when the adolescents were between ages 9–14 years (N=16,882). Participants predominately self-identified as non-Hispanic white (93%). More information about GUTS is available elsewhere (Field, et al., 1999). Institutional review board approval was obtained from Brigham and Women's Hospital.

Participants providing information on sexual orientation and drug use on at least one of three survey waves (1999, 2001, and 2003) were included in the analysis (N=12,644; 74.9% of original cohort). Among these participants, 64.8% responded to all 3 waves, 21.8% responded to 2 waves, and 13.4% responded to 1 wave. Sexual orientation reported in 1999 was unrelated to the number of waves of participation (p > .05).

2.2. Measures

2.2.1. Sexual Orientation—The sexual orientation question included on each of the 3 survey waves asked: "Which of the following best describes your feelings?" Response options were (1) completely heterosexual (attracted to persons of the opposite sex), (2) mostly heterosexual, (3) bisexual (equally attracted to men and women), (4) mostly homosexual, (5) completely homosexual (gay/lesbian, attracted to persons of the same sex), and (6) not sure. We combined "mostly homosexual" and "completely homosexual" into one lesbian/gay category because of the small number of respondents who chose these options. "Not sure" responses were excluded from analyses due to their small numbers and concentration at younger ages.

2.2.2. Drug Use—Participants were queried about their past-year use of marijuana, ecstasy (MDMA), cocaine, heroin, amphetamines (methamphetamine, speed), and LSD/mushrooms (psilocybin) on the three survey waves. In addition to examining these drugs individually, we created a composite variable that included reports of any use of the illicit drugs other than marijuana. Participants were asked if they used any of the following drugs without a doctor's prescription: sleeping pills (Rohypnol, barbiturates, downers), pain killers (Percodan, codeine, Oxycontin), stimulants (Ritalin, Adderall) and benzodiazepines (Valium, Xanax, Librium). We combined any past-year misuse of prescription drugs into one category. Drug use variables were dichotomized into reports of any versus no past-year use.

2.3. Statistical Analyses

We conducted repeated measures analyses using GUTS data gathered from three survey waves. Gender-specific age-standardized prevalences of past-year drug use for each sexual orientation group were estimated. Multivariable generalized estimating equations (GEE) repeated measures modified Poisson regression (Zou, 2004) was used to estimate adjusted risk ratios (RR) and 95% confidence intervals (CI) for past-year drug use comparing mostly heterosexual, bisexual, and lesbian/gay respondents to same-sex heterosexual respondents. Models controlled for age, region of residence (West, Midwest, Northeast, South), and race/ethnicity (non-Hispanic white, other). GEE variance estimates account for the non-independent repeated measures from the same individual and the sibling clusters (Fitzmaurice, Laird, & Ware, 2004; Liang & Zeger, 1986).

We investigated whether gender and age [adolescence (12–17 years) versus emerging adulthood (18–23 years)] modified relationships between sexual orientation and marijuana use, any illicit drug other than marijuana, and prescription drug misuse. Models examining modification by gender included both genders and sexual-orientation-by-gender interaction terms. Models assessing modification by age were stratified by gender and included sexual-orientation-by-age interaction terms.

3. Results

3.1. Sexual Orientation Differences in Past-Year Prevalence of Drug Use

Mostly heterosexual, bisexual, and lesbian/gay youth were more likely to report using a variety of drugs in the prior year than their heterosexual peers (Table 1). Sexual orientation differences in drug use were generally larger among females and bisexuals. When gender modified the relationship between sexual orientation and drug use, the elevated risk experienced by sexual minorities relative to heterosexuals was larger among females than males. Gender-by-sexual-orientation statistical interactions comparing differences between mostly heterosexual females and males to differences between heterosexual females and males were significant for any illicit drug use other than marijuana (p=.02) and misuse of prescription drugs (p=.03) (interactions not included in Table 1). Gender-by-sexual-orientation interactions for bisexuals were significant for marijuana (p=.01) and marginally significant for any illicit drug other than marijuana (p=.09).

3.2. Sexual Orientation Differences in Drug Use by Developmental Period

Age-specific prevalences and adjusted risk ratios indicated elevated risk for drug use in both age periods for most sexual minority groups compared to heterosexuals (Table 2). However, sexual orientation differences were larger in adolescence than emerging adulthood. In 12–17 year olds, risk ratios associated with sexual minority subgroups ranged from 2 to 7. In the older group of 18–23 year olds, risk ratios diminished, though most remained significant. All sexual-orientation-by-age-group interactions were significant (p<.05) for marijuana use. Sexual-orientation-by-age-group interactions for any illicit drug use other than marijuana were significant for gay males (p<.0001) and bisexual females (p=.003) and suggestive for bisexual males (p=.09). Sexual-orientation-by-age-group interactions for misuse of prescription drugs were significant for gay males (p=.04) and bisexual females (p=.049).

4. Discussion

Results of this study demonstrate a heightened risk of past-year drug use among minority sexual orientation youth. In fact, drug use prevalences observed among the sexual minorities in GUTS were much higher than prevalences observed among same-aged respondents of the representative 2002 National Survey of Drug Use and Health, suggesting that sexual minority youth who are children of health care professionals are not protected from drug use.

While supporting previous findings (e.g., Boyd, McCabe, & d'Arcy, 2003; Hahm, Wong, Huang, Ozonoff, & Lee, 2008; McCabe, Boyd, Hughes, & d'Arcy, 2003; Orenstein, 2001), our study builds on the existing literature by illuminating how drug use risk associated with sexual orientation is modified by gender and age. Among heterosexuals, males had higher prevalence of past-year drug use than females. Conversely, this pattern was reversed for minority sexual orientation youth, with females showing higher prevalence than males. This was evident even for amphetamine use, which is commonly known to be a problem among gay and bisexual males (Cabaj, Galanter, & Kleber, 2008), but less recognized as a drug that may also be used by lesbian and bisexual females. When gender modified associations between sexual orientation and drug use, larger sexual orientation differences were observed among females than males. Bisexual females had the highest past-year prevalence of drug use for all drug categories examined except heroin. These findings are congruent with a recent meta-analysis finding that sexual orientation disparities in substance use were largest in females and bisexuals (Marshal, et al., 2008). Possible explanations for these inequalities must be examined and may include psychosocial factors related to gender expression, gender differences in how young women and men experience and cope with the stress of stigma and discrimination, biological

factors, or joint effects of these factors (Rosario, Schrimshaw, & Hunter, 2008; Wilson & Rahman, 2005).

While sexual minority youth in this study were at elevated risk of past-year drug use during adolescence and emerging adulthood, disparities were amplified during adolescence when youth may be less well equipped developmentally to cope with the challenges of having a minority sexual orientation in a stigmatizing environment. This potential age disparity is alarming because younger onset of substance use is a robust predictor of later substance dependence (Anthony & Petronis, 1995; Grant & Dawson, 1998; Lynskey, Vink, & Boomsma, 2006). Community studies of lesbian, gay, and bisexual youth suggest that younger age of recognizing and disclosing a minority sexual orientation are risk factors for experiencing maltreatment and poorer mental health (D'Augelli, et al., 2005; Hershberger, Pilkington, & D'Augelli, 1997; Pilkington & D'Augelli, 1995). It is possible that such vulnerabilities may also increase drug use risk.

The extent that sexual orientation differences in age of onset of drug use may contribute to disparities in developmental outcomes and substance disorders requires further investigation. Sexual minority adults may suffer disproportionately from dysfunctional drug use (Cochran, Ackerman, Mays, & Ross, 2004) and substance/abuse dependence compared to heterosexuals (Meyer, 2003). Sexual minorities also experience barriers to accessing services for substance problems (Corliss, Grella, Mays, & Cochran, 2006); when they do present for treatment, they may display greater co-morbid psychopathology and substance problems than heterosexuals (Cochran & Cauce, 2006). Given that substance abuse treatment programs typically do not address the needs of lesbian, gay, and bisexual individuals (Cochran, Peavy, & Robohm, 2007; Matthews & Selvidge, 2005), prevention efforts are vital.

Study limitations include limited generalizability because GUTS is not a representative sample and the majority of participants are non-Hispanic white. Nonetheless, participants were enrolled into GUTS independent of their sexual orientation. Thus, findings are presumably less biased than what is characteristic of samples recruited through gay community settings. In addition, findings are based on self-reports of drug use. Longitudinal studies may also suffer from attrition bias, but how loss-to-follow-up might influence sexual orientation estimates of drug use is not known.

5. Conclusions

This study provides further evidence that minority sexual orientation is a risk indicator for illicit drug use and misuse of prescription drugs during adolescence. Despite evidence that minority sexual orientation youth are at elevated risk for a variety of health concerns, including drug use, the health professions do not effectively address the specific needs of this population (Corliss, Shankle, & Moyer, 2007; Sanchez, Rabatin, Sanchez, Hubbard, & Kalet, 2006; Tesar & Rovi, 1998). While the reasons that these youth are at high risk for substance use are not completely understood, societal stigma of homosexuality is believed to play an important role. The American Academy of Pediatrics recognizes sexual minority youths' unique health concerns and has issued guidelines for their care (Frankowski, 2004). Providers should routinely ask youth about their sexual orientation and substance use and refer those needing additional support to culturally-competent and appropriate services. Additional efforts and resources are required to reduce the health disparities affecting this population. Efforts should focus on young minority sexual orientation adolescents because vulnerability is heightened during this developmental period.

Acknowledgments

This study was funded by grants DA23610, HD45763, DK46834, and HL03533 from the National Institutes of Health, grant RSGPB-04-009-01-CPPB from the American Cancer Society, and the Robert Wood Johnson Foundation. Drs. Corliss and Austin were also supported by the Leadership Education in Adolescent Health Project, Maternal and Child Health Bureau, Health Resources and Services Administration grant 6T71-MC00009-16. The authors would like to thank the participants of the Growing Up Today Study and the members of the Growing Up Today Study research team whose dedication made this study possible.

Role of Funding Sources

Funding sources had no role in the study design, collection, analysis or interpretation of the data, writing the manuscript, or the decision to submit the paper for publication.

References

- Anthony JC, Petronis KR. Early-onset drug use and risk of later drug problems. Drug Alcohol Depend 1995;40(1):9–15. [PubMed: 8746919]
- Arnett JJ. Emerging adulthood: A theory of development from the late teens through the twenties. American Psychologist 2000;55(5):469–480. [PubMed: 10842426]
- Boyd CJ, McCabe SE, d'Arcy H. Ecstasy use among college undergraduates: gender, race and sexual identity. J Subst Abuse Treat 2003;24(3):209–215. [PubMed: 12810141]
- Brigham and Women's Hospital and Harvard Medical School. Nurses' Health Study. 2009 [Accessed June 10, 2009]. Available at: http://www.channing.harvard.edu/nhs/
- Cabaj, RP.; Galanter, M.; Kleber, HD. The American Psychiatric Publishing textbook of substance abuse treatment. 4th ed.. Arlington, VA: US: American Psychiatric Publishing, Inc.; 2008. Gay men and lesbians; p. 623-638.
- Cochran BN, Cauce AM. Characteristics of lesbian, gay, bisexual, and transgender individuals entering substance abuse treatment. J Subst Abuse Treat 2006;30(2):135–146. [PubMed: 16490677]
- Cochran BN, Peavy KM, Robohm JS. Do specialized services exist for LGBT individuals seeking treatment for substance misuse? A study of available treatment programs. Subst Use Misuse 2007;42 (1):161–176. [PubMed: 17366131]
- Cochran SD, Ackerman D, Mays VM, Ross MW. Prevalence of non-medical drug use and dependence among homosexually active men and women in the US population. Addiction 2004;99(8):989–998. [PubMed: 15265096]
- Corliss HL, Grella CE, Mays VM, Cochran SD. Drug use, drug severity, and help-seeking behaviors of lesbian and bisexual women. J Womens Health 2006;15(5):556–568.
- Corliss HL, Shankle MD, Moyer MB. Research, curricula, and resources related to lesbian, gay, bisexual, and transgender health in US schools of public health. Am J Public Health 2007;97(6):1023–1027. [PubMed: 17463373]
- D'Augelli AR, Grossman AH, Salter NP, Vasey JJ, Starks MT, Sinclair KO. Predicting the suicide attempts of lesbian, gay, and bisexual youth. Suicide and Life-Threatening Behavior 2005;35(6): 646–660. [PubMed: 16552980]
- Eisenberg M, Wechsler H. Substance use behaviors among college students with same-sex and opposite-sex experience: results from a national study. Addict Behav 2003;28(5):899–913. [PubMed: 12788264]
- Faulkner AH, Cranston K. Correlates of same-sex sexual behavior in a random sample of Massachusetts high school students. Am J Public Health 1998;88(2):262–266. [PubMed: 9491018]
- Fergusson DM, Boden JM, Horwood LJ. Cannabis use and other illicit drug use: testing the cannabis gateway hypothesis. Addiction 2006;101(4):556–569. [PubMed: 16548935]
- Field AE, Camargo CA Jr, Taylor CB, Berkey CS, Frazier AL, Gillman MW, et al. Overweight, weight concerns, and bulimic behaviors among girls and boys. J Am Acad Child Adolesc Psychiatry 1999;38 (6):754–760. [PubMed: 10361795]
- Fitzmaurice, GM.; Laird, NM.; Ware, JH. Applied Longitudinal Analysis. Hoboken, New Jersey: John Wiley & Sons, Inc.; 2004.

Ford JA, Jasinski JL. Sexual orientation and substance use among college students. Addict Behav 2006;31 (3):404–413. [PubMed: 15970397]

- Frankowski BL. Sexual orientation and adolescents. Pediatrics 2004;113(6):1827–1832. [PubMed: 15173519]
- Garofalo R, Wolf RC, Kessel S, Palfrey SJ, DuRant RH. The association between health risk behaviors and sexual orientation among a school-based sample of adolescents. Pediatrics 1998;101(5):895–902. [PubMed: 9565422]
- Grant BF, Dawson DA. Age of onset of drug use and its association with DSM-IV drug abuse and dependence: results from the National Longitudinal Alcohol Epidemiologic Survey. J Subst Abuse 1998;10(2):163–173. [PubMed: 9854701]
- Hahm HC, Wong FY, Huang ZJ, Ozonoff A, Lee J. Substance use among Asian Americans and Pacific Islanders sexual minority adolescents: findings from the National Longitudinal Study of Adolescent Health. J Adolesc Health 2008;42(3):275–283. [PubMed: 18295136]
- Hershberger SL, Pilkington NW, D'Augelli AR. Predictors of suicide attempts among gay, lesbian, and bisexual youth. J Adolescent Res 1997;12(4):477–497.
- Liang K-Y, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika 1986;73:13–22.
- Lubman DI, Yucel M, Hall WD. Substance use and the adolescent brain: a toxic combination? J Psychopharmacol 2007;21(8):792–794. [PubMed: 17984159]
- Lynskey MT, Vink JM, Boomsma DI. Early onset cannabis use and progression to other drug use in a sample of Dutch twins. Behav Genet 2006;36(2):195–200. [PubMed: 16402286]
- Marshal MP, Friedman MS, Stall R, King KM, Miles J, Gold MA, et al. Sexual orientation and adolescent substance use: a meta-analysis and methodological review. Addiction 2008;103(4):546–556. [PubMed: 18339100]
- Matthews CR, Selvidge MM. Lesbian, gay, and bisexual clients' experiences in treatment for addiction. J Lesbian Stud 2005;9(3):79–90. [PubMed: 17548287]
- McCabe SE. Correlates of nonmedical use of prescription benzodiazepine anxiolytics: results from a national survey of U.S. college students. Drug Alcohol Depend 2005;79(1):53–62. [PubMed: 15943944]
- McCabe SE, Boyd C, Hughes TL, d'Arcy H. Sexual identity and substance use among undergraduate students. Subst Abus 2003;24(2):77–91. [PubMed: 12766375]
- Meyer IH. Prejudice, social stress, and mental health in lesbian, gay, and bisexual populations: conceptual issues and research evidence. Psychol Bull 2003;129(5):674–697. [PubMed: 12956539]
- Orenstein A. Substance use among gay and lesbian adolescents. J Homosex 2001;41(2):1–15. [PubMed: 11482423]
- Pilkington NW, D'Augelli AR. Victimization of lesbian, gay, and bisexual youth in community settings. J Community Psychol 1995;23(1):34–56.
- Rosario M, Hunter J, Gwadz M. Exploration of substance use among lesbian, gay, and bisexual youth: prevalence and correlates. Journal of Adolescent Research 1997;12(4):454–476.
- Rosario M, Schrimshaw EW, Hunter J. Butch/femme differences in substance use and abuse among young lesbian and bisexual women: examination and potential explanations. Substance Use & Misuse 2008;43(8):1002–1015. [PubMed: 18649226]
- Russell ST, Driscoll AK, Truong N. Adolescent same-sex romantic attractions and relationships: implications for substance use and abuse. Am J Public Health 2002;92(2):198–202. [PubMed: 11818291]
- Sanchez NF, Rabatin J, Sanchez JP, Hubbard S, Kalet A. Medical students' ability to care for lesbian, gay, bisexual, and transgendered patients. Fam Med 2006;38(1):21–27. [PubMed: 16378255]
- Substance Abuse and Mental Health Services Administration, Office of Applied Studies. Results from the 2007 National Survey on Drug Use and Health: National Findings. (NSDUH Series H-34, DHHS Publication No. SMA 08-4343). Rockville, MD: 2008.
- Tesar CM, Rovi SL. Survey of curriculum on homosexuality/bisexuality in departments of family medicine. Fam Med 1998;30(4):283–287. [PubMed: 9568499]

Wilson, G.; Rahman, Q. Born gay: The psychobiology of sex orientation. London, UK: Peter Owen Publishers; 2005.

Zou G. A modified Poisson regression approach to prospective studies with binary data. Am J Epidemiol 2004;159(7):702–706. [PubMed: 15033648]

NIH-PA Author Manuscript

NIH-PA Author Manuscript

(1999-2005)
cohort
e GUTS
ears) in the
(12–23 year
youth (1
nd male
female a
on among
orientati
y sexual
ug use ^a b
t-year dru
Past-

Table 1

Heterosexuma		4	Age-standardized prevalence (%)	evalence (%)				Adjusted	Adjusted RR (95% CD^b		
in like 428 \$9.9 \$49.6 \$1.97* (1.82.213) \$2.63* (2.35.288) \$1.74* (1.82.213) \$2.63* (2.25.288) \$1.74* (1.82.213) \$2.09* (1.29.2.20) \$1.56* (1.29.2.20) \$1.56* (1.29.2.20) \$1.56* (1.29.2.20) \$1.56* (1.29.2.20) \$1.56* (1.29.2.20) \$1.56* (1.29.2.20) \$1.56* (1.29.2.20) \$1.56* (1.29.2.20) \$1.56* (1.29.2.20) \$1.56* (1.29.2.20) \$1.50* (1.29.2.20) \$1.50* (1.29.2.20) \$1.50* (1.29.2.20) \$1.50* (1.29.2.20) \$1.50* (1.29.2.20) \$1.50* (1.29.2.20) \$1.50* (1.29.2.20) \$1.50* (1.29.2.20) \$1.50* (1.29.2.20) \$1.50* (1.29.2.20) \$1.50* (1.29.2.20) \$1.50* (1.29.2.20) \$1.50* (1.29.2.20) \$1.50* (1.29.2.20) \$1.50* (1.29.2.20) \$1.50* (1.29.2.20) \$1.50* (1.29.2.2.20) \$1.50* (1.29.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2	Drug use by gender	Completely Heterosexual	Mostly Heterosexual	Bisexual	Lesbian/ Gay	Mostly	Heterosexual		isexual	Les	bian/Gay
tic due other days and days are days as days a	Marijuana										
siding other signature and seed at a	Female	18.6	42.8	59.9	49.6	1.97*	(1.82, 2.13)	2.63*	(2.35, 2.98)	1.74*	(1.29, 2.36)
ii dug other 4.4	Male	20.9	41.9	38.5	32.1	1.87*	(1.65, 2.13)	1.72*	(1.29, 2.30)	1.56*	(1.21, 2.01)
e 44 175 31.1 210 340* (291,397) 5.13* (405,650) 307* e 59 150 204 133 2.32* (178,303) 2.87* (164,503) 1.89* e 1.8 8.0 14.8 8.7 3.91* (307,497) 6.68* (4.74,940) 4.56* e 1.7 4.2 12.3 7.4 2.19* (1.23,390) 6.27* (4.74,940) 4.56* e 1.3 7.2 9.8 6.9 3.38* (2.61,439) 4.06* (4.74,940) 4.56* e 1.3 2.2 6.8 2.67* (1.73,413) 1.29 (3.01,131) 2.92* e 0.1 0.2 6.8 2.67* (1.73,413) 1.29 0.34,88) 2.48* e 0.2 1.3 2.6 5.33* (1.84,15.5) 7.35 (0.92,58.8) 6.61* e 1.3 1.4 8.3 3.94* (2.14,56)	Any illicit drug other than marijuana										
Ee 15.0 20.4 13.3 2.32* (1.78, 3.03) 2.87* (1.64, 5.03) 1.89* 1.8 8.0 14.8 8.7 391* (3.07, 4.97) 6.68* (4.74, 9.40) 4.56* 1.7 4.2 12.3 7.4 2.19* (1.23, 3.90) 6.27* (301, 131) 2.92* 1.8 7.2 9.8 6.9 3.38* (2.61, 4.39) 4.06* (3.01, 131) 2.92* 1.8 7.1 3.2 6.8 2.67* (1.73, 4.19) 1.29 (3.01, 131) 2.92* 1.8 7.1 3.2 6.8 2.67* (1.73, 4.19) 1.29 (3.44, 4.85) 2.48* 0.24, 4.89 2.48* 0.24, 4.89 2.48* 0.24, 4.89 2.48* 0.24, 4.89 2.48* 0.24* 0.24, 4.89 2.48* 0.24* 0.24, 4.89 2.48* 0.24* 0.24, 4.89 0.24* 0.24* 0.24* 0.24* 0.24* 0.24* 0.24* 0.24* 0.24* 0.24* 0.24* <	Female	4.4	17.5	31.1	21.0	3.40*	(2.91, 3.97)	5.13*	(4.05, 6.50)	3.07*	(1.70, 5.55)
le 1.8 8.0 14.8 8.7 3.91* (3.07,4.97) 6.68* (4.74,9.40) 4.56* (4.76,9.40) 4.56* (4.7	Male	5.9	15.0	20.4	13.3	2.32*	(1.78, 3.03)	2.87*	(1.64, 5.03)	1.89*	(1.17, 3.06)
led 1.8 8.0 14.8 8.7 3.91* (3.07.4.97) 6.68* (4.74.9.40) 4.56* (4.57.4.94) 1.2 3.91* (3.07.4.97) 6.68* (4.74.9.40) 4.56* (4.56* 6.57* (3.01.13.1) 2.92* (3.01.13.1) 2.92* (3.01.13.1) 2.92* (3.01.13.1) 2.92* (3.01.13.1) 2.92* (3.01.13.1) 2.92* (3.01.13.1) 2.93* (3.0	Ecstasy										
L3	Female	1.8	8.0	14.8	8.7	3.91*	(3.07, 4.97)	*89.9	(4.74, 9.40)	4.56*	(2.12, 9.87)
le 1.8 7.2 9.8 6.9 3.38* (2.61,4.39) 4,06* (2.60,6.34) 3.57* 6.8 2.67* (1.73,4.13) 1.29 (0.34,4.85) 2.48* 6.8 2.67* (1.73,4.13) 1.29 (0.34,4.85) 2.48* 6.8 2.67* (1.73,4.13) 1.29 (0.34,4.85) 2.48* 6.8 2.8 2.67* (1.73,4.13) 1.29 (0.34,4.85) 2.48* 6.8 2.8 2.8 2.33* (1.84,15.5) 2.35* (0.92,5.8) 2.48* 6.8 2.8 2.33* (1.84,15.5) 2.35* (0.92,5.8) 2.35* (0.92,5.8) 2.35* (0.92,5.8) 2.35* (0.92,5.8) 2.35* (0.92,5.8) 2.35* (0.92,5.8) 2.35* (0.92,5.8) 2.37* (0.92,5.8) 2.30* (0.92,5.8) 2.30* (0.92,5.8) 2.30* (0.92,5.8) 2.30* (0.92,5.8) 2.30* (0.92,5.8) 2.30* (0.92,5.8) 2.33* (0.92,5.9) 2.33* (0.92,5.8) 2.33*	Male	1.7	4.2	12.3	7.4	2.19*	(1.23, 3.90)	6.27*	(3.01, 13.1)	2.92*	(1.34, 6.39)
led 1.8 7.2 9.8 6.9 3.38* (2.61,4.39) 4.06* (2.60,6.34) 3.57* (3.61,4.39) 4.06* (2.60,6.34) 3.57* (3.61,4.39) (3.61,4.39) (3.61,4.39) (3.61,4.85) (3.6	Cocaine										
Le 0.1 0.9 0.8 0 0 7.80* (1.73,4.13) 1.29 (0.34,4.85) 2.48* 0.24* 0.34,4.85 0.24* 0.	Female	1.8	7.2	8.6	6.9	3.38*	(2.61, 4.39)	*4.06	(2.60, 6.34)	3.57*	(1.58, 8.08)
le 0.1 0.9 0.8 0 7.80* (3.97, 15.3) 5.49* (1.21, 24.9) c amines 0.2 1.0 1.3 2.6 5.33* (1.84, 15.5) 7.35 (0.92, 58.8) 6.61* 0.61* 0.61* 0.62* 0.6	Male	2.4	7.1	3.2	8.9	2.67*	(1.73, 4.13)	1.29	(0.34, 4.85)	2.48*	(1.23, 5.00)
0.1 0.9 0.8 0 7.80* (3.97, 15.3) 5.49* (1.21, 24.9) c 0.2 1.0 1.3 2.6 5.33* (1.84, 15.5) 7.35 (0.92, 38.8) 6.61* 1.3 5.7 14.7 8.3 3.98* (2.94, 5.38) 9.35* (6.34, 13.8) 4.56* 1.5 5.6 6.2 4.5 3.71* (2.32, 5.96) 3.90* (1.34, 11.2) 3.07* 2.3 9.7 19.3 14.3 3.84* (3.10, 4.76) 6.40* (4.64, 8.81) 4.91* 4.2 8.0 8.2 2.33* (1.66, 3.25) 1.46 (0.53, 4.03) 1.87*	Heroin										
0.2 1.0 1.3 2.6 5.33* (1.84, 15.5) 7.35 (0.92, 58.8) 6.61* 1.3 5.7 14.7 8.3 3.98* (2.94, 5.38) 9.35* (6.34, 13.8) 4.56* 1.5 5.6 6.2 4.5 3.71* (2.32, 5.96) 3.90* (1.34, 11.2) 3.07* 2.3 9.7 19.3 14.3 3.84* (3.10, 4.76) 6.40* (4.64, 8.81) 4.91* 4.2 11.5 8.0 8.2 2.33* (1.66, 3.25) 1.46 (0.53, 4.03) 1.87*	Female	0.1	6.0	8.0	0	7.80*	(3.97, 15.3)	5.49*	(1.21, 24.9)	c	c
1.3 5.7 14.7 8.3 3.98* (2.94,5.38) 9.35* (6.34,13.8) 4.56* 0 1.5 5.6 6.2 4.5 3.71* (2.32,5.96) 3.90* (1.34,11.2) 3.07* 0 2.3 9.7 19.3 14.3 3.84* (3.10,4.76) 6.40* (4.64,8.81) 4.91* 0 4.2 11.5 8.0 8.2 2.33* (1.66,3.25) 1.46 (0.53,4.03) 1.87* 0	Male	0.2	1.0	1.3	2.6	5.33*	(1.84, 15.5)	7.35	(0.92, 58.8)	6.61*	(1.44, 30.3
1.3 5.7 14.7 8.3 3.98* (2.94,5.38) 9.35* (6.34,13.8) 4.56* 1.5 5.6 6.2 4.5 3.71* (2.32,5.96) 3.90* (1.34,11.2) 3.07* 6.2 2.3 9.7 19.3 14.3 3.84* (3.10,4.76) 6.40* (4.64,8.81) 4.91* 6.40* 4.2 11.5 8.0 8.2 2.33* (1.66,3.25) 1.46 (0.53,4.03) 1.87* 6.40*	Amphetamines										
1.5 5.6 6.2 4.5 3.71* $(2.32, 5.96)$ 3.90* $(1.34, 11.2)$ 3.07* 2.3 9.7 19.3 14.3 3.84* $(3.10, 4.76)$ 6.40* $(4.64, 8.81)$ 4.91* 4.91 * 4.2 11.5 8.0 8.2 2.33 * $(1.66, 3.25)$ 1.46 $(0.53, 4.03)$ 1.87*	Female	1.3	5.7	14.7	8.3	3.98*	(2.94, 5.38)	9.35*	(6.34, 13.8)	4.56*	(1.30, 16.1)
2.3 9.7 19.3 14.3 3.84^* $(3.10, 4.76)$ 6.40^* $(4.64, 8.81)$ 4.91^* 4.2 11.5 8.0 8.2 2.33^* $(1.66, 3.25)$ 1.46 $(0.53, 4.03)$ 1.87^*	Male	1.5	5.6	6.2	4.5	3.71*	(2.32, 5.96)	3.90*	(1.34, 11.2)	3.07*	(1.30, 7.27)
2.3 9.7 19.3 14.3 3.84^* $(3.10, 4.76)$ 6.40^* $(4.64, 8.81)$ 4.91^* 4.2 11.5 8.0 8.2 2.33^* $(1.66, 3.25)$ 1.46 $(0.53, 4.03)$ 1.87^*	LSD/Mushrooms										
4.2 11.5 8.0 8.2 $2.33*$ $(1.66, 3.25)$ 1.46 $(0.53, 4.03)$ $1.87*$	Female	2.3	7.6	19.3	14.3	3.84*	(3.10, 4.76)	6.40*	(4.64, 8.81)	4.91*	(2.64, 9.12)
	Male	4.2	11.5	8.0	8.2	2.33*	(1.66, 3.25)	1.46	(0.53, 4.03)	1.87*	(1.04, 3.35)
	Misuse of prescription										

	Gay	(0.87, 3.88)	(1.29, 3.21)
	Lesbian/Gay	1.84 ((2.04*
Adjusted RR (95% $\mathrm{CI})^b$	Bisexual	4.07^* (3.21, 5.16)	(1.41, 4.72)
Adjusted Rl	Bis	4.07*	2.58*
	Mostly Heterosexual	2.74* (2.37, 3.17)	(1.44, 2.56)
	Mostly F	2.74*	1 92*
	Lesbian/ Gay	16.5	13.0
valence (%)	Bisexual Lesbian/ Gay	27.8	16.4
Age-standardized prevalence (%)	Mostly Heterosexual	16.6	11.4
Ā	Completely Heterosexual	5.7	0.9
	Drug use by gender	Female	Male

Corliss et al.

Abbreviations: RR, Risk Ratio; CI, Confidence Interval.

^aResults based on repeated measures observations. Among females, number of observations is 15051 completely heterosexual, 1313 mostly heterosexual, and 63 lesbian. Among males, number of observations is 9667 completely heterosexual, 391 mostly heterosexual, 63 bisexual, and 130 gay.

bMultivariable generalized estimating equations models adjust for age, race/ethnicity, and region of residence. All within-gender comparisons used completely heterosexual individuals as the referent group.

 $^{\mathcal{C}}$ Cannot be estimated because no lesbians reported heroin use.

* Statistically significant (p<.05).

Page 10

(1.72, 5.81)

3.16* 1.55

(2.02, 7.80) (0.67, 4.16)

3.97* 1.68

(1.04, 2.58)

1.64*

16.1

18.9

8.1

Misuse of prescription drugs 12–17 18–23

7.7

NIH-PA Author Manuscript

Table 2

NIH-PA Author Manuscript

Age-specific past-year drug use^a by sexual orientation among female and male youth in the GUTS cohort (1999–2005)

		Prevalence (%)	(%)				Adjusted	Adjusted RR (95% $\mathrm{CI})^{b}$		
Drug use by gender and age period (years)	Completely Heterosexual	Mostly Heterosexual	Bisexual	Lesbian/ Gay	Mostly	Mostly Heterosexual	<u> </u>	Bisexual	Les	Lesbian/Gay
Females										
Marijuana										
12–17	11.6	35.8	60.2	50.0	2.42*	(2.16, 2.71)	3.53*	(2.95, 4.22)	2.57*	(1.49, 4.42)
18–23	27.6	56.8	67.2	55.3	1.81*	(1.64, 1.99)	2.41*	(2.11, 2.75)	1.81*	(1.36, 2.40)
Any illicit drug other than marijuana										
12–17	2.7	12.9	28.9	25.0	3.94*	(3.13, 4.95)	7.62*	(5.57, 10.4)	4.85*	(1.54, 15.3)
18–23	6.7	25.6	35.9	25.5	3.38*	(2.80, 4.09)	4.94*	(3.75, 6.51)	3.18*	(1.76, 5.76)
Misuse of prescription drugs										
12–17	5.2	15.1	31.3	18.8	2.62*	(2.15, 3.21)	5.19*	(3.95, 6.83)	2.71	(0.86, 5.59)
18–23	6.4	20.0	25.9	12.8	3.01*	(2.47, 3.68)	3.77*	(2.68, 5.29)	1.94	(0.87, 4.30)
Males										
Marijuana										
12–17	12.9	33.6	32.4	33.9	2.24*	(1.87, 2.70)	2.05*	(1.34, 3.15)	2.09*	(1.45, 3.02)
18–23	32.5	56.2	50.0	40.5	1.64*	(1.39, 1.94)	*44*	(1.01, 2.07)	1.28	(0.93, 1.77)
Any illicit drug other than marijuana										
12–17	3.0	8.5	18.9	17.9	2.45*	(1.59, 3.76)	5.07*	(2.49, 10.3)	4.46*	(2.42, 8.25)
18–23	10.0	25.7	23.1	10.8	2.53*	(1.82, 3.53)	1.91	(0.74, 4.94)	1.07	(0.55, 2.05)

Abbreviations: RR, Risk Ratio; CI, Confidence Interval.

^aResults based on repeated measures observations. Among females, number of observations is 15051 completely heterosexual, 1313 mostly heterosexual, 259 bisexual, and 63 lesbian. Among males, number of observations is 9667 completely heterosexual, 391 mostly heterosexual, 63 bisexual, and 130 gay.

b Multivariable generalized estimating equations models adjust for age, race/ethnicity, and region of residence. All within-gender comparisons used completely heterosexual individuals as the referent group.

Multivariable generalized estimating equations inodess adjust for age, face elimicity, and region of resource. At * Statistically significant (p<.05).